ATE99941T1 - Medikamente enthaltend salmeterol und fluticason. - Google Patents

Medikamente enthaltend salmeterol und fluticason.

Info

Publication number
ATE99941T1
ATE99941T1 AT90309846T AT90309846T ATE99941T1 AT E99941 T1 ATE99941 T1 AT E99941T1 AT 90309846 T AT90309846 T AT 90309846T AT 90309846 T AT90309846 T AT 90309846T AT E99941 T1 ATE99941 T1 AT E99941T1
Authority
AT
Austria
Prior art keywords
fluticasone
salmeterol
medications containing
containing salmeterol
medications
Prior art date
Application number
AT90309846T
Other languages
German (de)
English (en)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE99941(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE99941T1 publication Critical patent/ATE99941T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT90309846T 1989-09-08 1990-09-07 Medikamente enthaltend salmeterol und fluticason. ATE99941T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
ATE99941T1 true ATE99941T1 (de) 1994-01-15

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90309846T ATE99941T1 (de) 1989-09-08 1990-09-07 Medikamente enthaltend salmeterol und fluticason.

Country Status (20)

Country Link
EP (1) EP0416951B1 (OSRAM)
JP (1) JP3042867B2 (OSRAM)
AT (1) ATE99941T1 (OSRAM)
BE (1) BE1003053A3 (OSRAM)
CA (1) CA2024916C (OSRAM)
CH (1) CH680983C9 (OSRAM)
DE (2) DE19975040I2 (OSRAM)
DK (1) DK0416951T3 (OSRAM)
ES (1) ES2062392T3 (OSRAM)
FR (1) FR2651677B1 (OSRAM)
HK (1) HK18695A (OSRAM)
HU (1) HU211272A9 (OSRAM)
IE (1) IE65535B1 (OSRAM)
IL (1) IL95590A (OSRAM)
IT (1) IT1241996B (OSRAM)
LU (1) LU90392I2 (OSRAM)
NL (1) NL990012I2 (OSRAM)
NZ (1) NZ235221A (OSRAM)
PH (1) PH27594A (OSRAM)
SG (1) SG166294G (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
SK285910B6 (sk) * 1991-12-18 2007-10-04 Aktiebolaget Astra Medicinálny produkt obsahujúci kombináciu formoterolu a budesonidu
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
CA2317999C (en) 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
EP1248597B1 (en) * 1999-12-24 2005-03-30 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU2001276497B2 (en) * 2000-08-05 2005-04-07 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ATE411334T1 (de) 2001-04-30 2008-10-15 Glaxo Group Ltd Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.- zyklischen estergruppe
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
AU2003221482A1 (en) * 2002-03-04 2003-09-16 Boehringer Ingelheim Pharma Gmbh And Co. Kg Novel cinnamate salts, method for production and use thereof as medicaments
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
CA2534934A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
MX2009006787A (es) 2006-12-22 2009-07-10 Almirall Lab Dispositivo de inhalacion para medicamentos en forma de polvo.
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
RU2015150970A (ru) * 2013-04-29 2017-06-07 Санофи Са Вдыхаемые фармацевтические композиции и ингаляторные устройства для таких композиций

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
FR2651677A1 (fr) 1991-03-15
HU211272A9 (en) 1995-11-28
CA2024916C (en) 2002-07-09
NZ235221A (en) 1992-11-25
BE1003053A3 (fr) 1991-11-05
NL990012I1 (nl) 1999-07-01
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
SG166294G (en) 1995-06-16
CH680983C1 (OSRAM) 2008-06-25
DK0416951T3 (da) 1994-02-14
DE19975040I2 (de) 2006-07-13
PH27594A (en) 1993-08-31
EP0416951B1 (en) 1994-01-12
CH680983A5 (OSRAM) 1992-12-31
DE69005951T2 (de) 1994-05-26
IE65535B1 (en) 1995-11-01
EP0416951A1 (en) 1991-03-13
HK18695A (en) 1995-02-17
IL95590A (en) 1996-06-18
CH680983C9 (OSRAM) 2008-08-15
IT1241996B (it) 1994-02-02
LU90392I2 (fr) 1999-06-28
DE69005951D1 (de) 1994-02-24
IL95590A0 (en) 1991-09-16
FR2651677B1 (fr) 1993-08-06
JP3042867B2 (ja) 2000-05-22
IT9048260A0 (it) 1990-09-07
IE903256A1 (en) 1991-03-13
JPH03167120A (ja) 1991-07-19
CA2024916A1 (en) 1991-03-09
NL990012I2 (nl) 1999-09-01

Similar Documents

Publication Publication Date Title
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
DE69002718D1 (de) Medikamente.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
CA2123909A1 (en) New combination of formoterol and budesonide
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69918961D1 (de) Verbesserte inhalationspräparate
MY111155A (en) Medicaments
JPS6438027A (en) Remedy for cancer
RU93003456A (ru) Лекарственный препарат
RU93003454A (ru) Лекарственный препарат